IL17RA and prostate cancer: To our best knowledge, our group first reported that IL-17RA was constitutively phosphorylated by GSK3 at threonine 780 (T780), leading to ubiquitylation and degradation, and that IL-17RA phosphorylation was reduced in prostate cancer tissues compared to normal control tissues [25].